Presentation on theme: "InGenius HyperCare Progress to Goal Alberto Zanchetti Coordinator."— Presentation transcript:
1InGenius HyperCareProgress to GoalAlberto ZanchettiCoordinator
2Integrating Genomics, Clinical Research and InGenious HyperCareNetwork of ExcellenceIntegrating Genomics, Clinical Research andCare in HypertensionInGenious HyperCare
3InGenious HyperCare : Partners Italy1. Ist. Auxologico It., Milan (A. Zanchetti)2. Un. Milano Bicocca (G. Mancia)3. Un. Milano (D. Cusi, F. Magrini)4. Un. Brescia (E. Agabiti-Rosei)5. Un. Roma-Sapienza (M. Volpe)6. Un. Padova (E. Casiglia)7. Un. Vita Salute, Milano (G. Bianchi)France8. INSERM Paris (S. Laurent)9. CHU Nancy (F. Zannad)United Kingdom10. Un. Glasgow (A. Dominiczak)11. Un. Manchester (A. Heagerty)12. Un. Leicester (B. Williams)Belgium13. KU Leuven (J. Staessen)Netherlands14. Un. Maastricht (H. Struijker-Boudier)Germany15. Charité, Berlin (T. Unger, F. Luft)16. MH Hannover (H. Haller)17. WWU Münster (E. Brand)Spain18. HCU Valencia (J. Redón)19. FIMA Navarra (J. Diez)20. Hosp. 12 Octubre, Madrid (L. Ruilope)21. HCP Barcelona (A. Coca)Sweden22. Un. Lund (O. Melander)Finland23. Un. Helsinki (S. Tuomilehto)Poland24. Med. Un. Gdansk (K. Narkiewicz)25. Jagellonian Med. Un. Cracow (K. Kawecka)Czech Rep.26. IKEM, Prague (R. Cifkova)27. Charles Un. Pilsen (J. Filipovsky)Switzerland28. Un. Lausanne (M. Burnier)Russia29. RAMS, Novosibirsk (Y. Nikitin)China30. IH Shanghai (J. Wang)SME31. Mosaiques (H. Mischak)32. CF Consulting (C. Finocchiaro)1473 Z
4Steering Committee Alberto Zanchetti (Network Coordinator) InGenious HyperCareSteering CommitteeAlberto Zanchetti (Network Coordinator)Javier Diez, Anna Dominiczak, Hermann Haller, Kalina Kawecka-Jaszcz, Giuseppe Mancia,Josep Redón, Jan Staessen, Faiez Zannad
5Hypertension and, more broadly, common cardiovascular diseases are due to complex interactions between environment and genetic background. This genetic background is also very complex, does not depend on alterations in single genes (except in rare cases), but on interactions between polymorphisms in a large number of genes, most of which are still unknown.
6Progress depends on concentrated efforts in order To study large numbers of subjects with different cv characteristics. To characterize subjects (phenotyping) in the most detailed and uniform way To approach the genetic background by exploring polymorphisms in multiple genes belonging to coherent pathophysiological pathways or families (mechanomics)
7InGenious HyperCareGeneral GoalsIntegrating complementary but still fragmented experiences inStudying the physiological mechanisms of blood pressure control and hypertension developmentPhenotyping initiation and progression of organ damageExploring genetics, genomics and proteomics of proneness to hypertension and hypertension-related cardiovascular disease
8InGenious HyperCareSpecific GoalsTo create large common databases of subjects with and without hypertension, with and without hypertension-related cardiovascular and renal diseaseTo establish joint platforms for phenotyping, genotyping, proteomic studies and statistical analysesTo initiate coordinated programmes of research activities
9Integrating Genomics, Clinical Research and Care in Hypertension The InGenious HyperCare European NetworkMilan, June 2007ProgrammeZanchetti (Milan): InGenious HyperCare - Plans and progressesT. Kuznetsova (Leuven): Excellence in phenotyping - Assessment of left ventricular functionJ. Diez (Pamplona): Excellence in phenotyping - Circulating markers of left ventricular dysfunctionJ. Redon (Valencia): Excellence in phenotyping - Renal function and microalbuminuriaA. Dominiczak (Glagow): Genome scans in complex traits: is hypertension a special case?
10Integrating Genomics, Clinical Research and Care in Hypertension A European Network Berlin, June 16, – Hall 61.Alberto Zanchetti (Milan, Italy) – InGenious HyperCare: Progress to goal 2.Anna Dominiczak (Glasgow, UK) – Genome-wide association studies in hypertension 3.Gianfranco Parati Milan, Italy) – Excellence in phenotyping: assessment of autonomic nervous system activity 4.Hermann Haller (Hannover, Germany) – Excellence in phenotyping: assessment of oxidative stress and microinflammation 5.Tatiana Kuznetsova (Leuven, Belgium) - Endogenous oubain: from genotypes to cardiovascular structure and function
11INTEGRATING GENOMICS, CLINICAL RESEARCH AND CARE IN HYPERTENSION: REPORT FROM A EUROPEAN NETWORK Sunday June 14, 2009 – Hall: BrownZanchetti A (Milan, Italy): Two-year progress toward integration Delles C (Glasgow, UK): Recruiting and phenotyping in family studies Kuznetsova T (Leuven, Belgium): Diagnostic criteria for subclinical systolic and diastolic left ventricular dysfunction Haller H (Hannover, Germany): Old and new markers for microinflammation: which are relevant? Lopez N (Pamplona, Spain; Nancy, France): New insight into biomarkers of hypertensive cardiac and vascular fibrosis Mischak H (Hannover, Germany): Proteome analysis as a powerful tool for prediction and assessment of cardiovascular disease General discussion